Aptahem AB (XSAT:APTA) 5-Year EBITDA Growth Rate: 60.50% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:APTA Aptahem AB XSAT:APTA
29 GF Score
Price kr0.49
! 1 Warning Sign
View Full Analysis

What is Aptahem AB 5-Year EBITDA Growth Rate?

Aptahem AB XSAT:APTA -0.81% 29 5-Year EBITDA Growth Rate is 60.50% as of Jun. 2026. GuruFocus rates XSAT:APTA with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Aptahem AB's EBITDA per Share for the three months ended in Jun. 2026 was kr-0.05.

During the past 3 years, the average EBITDA Per Share Growth Rate was 56.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 60.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 42.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aptahem AB was 67.00% per year. The lowest was -6.80% per year. And the median was 44.00% per year.

Aptahem AB  (XSAT:APTA) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Aptahem AB 5-Year EBITDA Growth Rate Related Terms

XSAT:APTA vs VRTX, REGN, MRNA: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Aptahem AB's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptahem AB 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptahem AB's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Aptahem AB's 5-Year EBITDA Growth Rate falls into.


XSAT:APTA
29GF Score
Aptahem AB XSAT:APTA
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptahem AB 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 60.50% mean?
Aptahem AB (XSAT:APTA) has a 5-Year EBITDA Growth Rate of 60.50% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Aptahem AB and its competitors.
Is Aptahem AB's 5-Year EBITDA Growth Rate too high?
Aptahem AB's current 5-Year EBITDA Growth Rate is 60.50%. Overall, Aptahem AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptahem AB's 5-Year EBITDA Growth Rate compare to VRTX and REGN?
Aptahem AB's 5-Year EBITDA Growth Rate of 60.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Aptahem AB and its competitors. Aptahem AB's current 5-Year EBITDA Growth Rate is 60.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptahem AB stock overvalued right now?
Aptahem AB (XSAT:APTA) has a current 5-Year EBITDA Growth Rate of 60.50%. The current 5-Year EBITDA Growth Rate is 60.50%. Aptahem AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aptahem AB (XSAT:APTA), the current 5-Year EBITDA Growth Rate is 60.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptahem AB Business Description

Address Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.
29GF Score

Get the complete analysis for XSAT:APTA

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.49
Price